Escitalopram for the Prevention of Peginterferon-α2a–Associated Depression
Authors: Martin Schaefer, Thomas Berg, Susanne Sarkar, Konrad Neumann
Journal: Annals of Internal Medicine (2013)

Letters15 January 2013Escitalopram for the Prevention of Peginterferon-α2a–Associated DepressionMartin Schaefer, MD, Thomas Berg, MD, Susanne Sarkar, and Konrad Neumann, PhDMartin Schaefer, MDFrom Kliniken Essen-Mitte, Essen, Germany; Clinic and Policlinic for Gastroenterology and Rheumatology, Universitätsklinikum Leipzig, Leipzig; Charité–Universitätsmedizin Berlin, Campus Charité Mitte, Berlin; and Institute for Biometry and Clinical Epidemiology, Charité–Universitätsmedizin Berlin, Campus Charité Benjamin Franklin, Berlin, Germany.Search for more papers by this author, Thomas Berg, MDFrom Kliniken Essen-Mitte, Essen, Germany; Clinic and Policlinic for Gastroenterology and Rheumatology, Universitätsklinikum Leipzig, Leipzig; Charité–Universitätsmedizin Berlin, Campus Charité Mitte, Berlin; and Institute for Biometry and Clinical Epidemiology, Charité–Universitätsmedizin Berlin, Campus Charité Benjamin Franklin, Berlin, Germany.Search for more papers by this author, Susanne SarkarFrom Kliniken Essen-Mitte, Essen, Germany; Clinic and Policlinic for Gastroenterology and Rheumatology, Universitätsklinikum Leipzig, Leipzig; Charité–Universitätsmedizin Berlin, Campus Charité Mitte, Berlin; and Institute for Biometry and Clinical Epidemiology, Charité–Universitätsmedizin Berlin, Campus Charité Benjamin Franklin, Berlin, Germany.Search for more papers by this author, and Konrad Neumann, PhDFrom Kliniken Essen-Mitte, Essen, Germany; Clinic and Policlinic for Gastroenterology and Rheumatology, Universitätsklinikum Leipzig, Leipzig; Charité–Universitätsmedizin Berlin, Campus Charité Mitte, Berlin; and Institute for Biometry and Clinical Epidemiology, Charité–Universitätsmedizin Berlin, Campus Charité Benjamin Franklin, Berlin, Germany.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-158-2-201301150-00020 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:On the basis of Dr. Landman's comments, we noticed that our primary entry in the ClinicalTrials.gov database was not updated with details of the final protocol and, indeed, included a mistake: The HAM-D was listed as the instrument for the primary outcome measurement instead of the MADRS. This has been communicated to the ClinicalTrials.gov registry so that a correction can be posted. Nevertheless, we must emphasize that the MADRS and not the HAM-D was defined as the primary outcome before any patient was included in our final study protocol, which was approved by the responsible ethics committee of ... Author, Article, and Disclosure InformationAffiliations: From Kliniken Essen-Mitte, Essen, Germany; Clinic and Policlinic for Gastroenterology and Rheumatology, Universitätsklinikum Leipzig, Leipzig; Charité–Universitätsmedizin Berlin, Campus Charité Mitte, Berlin; and Institute for Biometry and Clinical Epidemiology, Charité–Universitätsmedizin Berlin, Campus Charité Benjamin Franklin, Berlin, Germany.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M11-2214. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoEscitalopram for the Prevention of Peginterferon-α2a–Associated Depression in Hepatitis C Virus–Infected Patients Without Previous Psychiatric Disease Martin Schaefer , Rahul Sarkar , Viola Knop , Susanne Effenberger , Astrid Friebe , Loni Heinze , Ulrich Spengler , Thomas Schlaepfer , Jens Reimer , Peter Buggisch , Johann Ockenga , Ralph Link , Michael Rentrop , Hans Weidenbach , Gwendolyn Fromm , Klaus Lieb , Thomas F. Baumert , Andreas Heinz , Thomas Discher , Konrad Neumann , Stefan Zeuzem , and Thomas Berg Escitalopram for the Prevention of Peginterferon-α2a–Associated Depression Gijs W.D. Landman Metrics Cited ByMental disorders in HIV/HCV coinfected patients under antiviral treatment for hepatitis CTrust but Verify: Trial Registration and Determining Fidelity to the ProtocolDeborah A. Zarin, MD and Tony Tse, PhD 15 January 2013Volume 158, Issue 2Page: 140KeywordsConflicts of interestDatabasesDisclosureHepatitis C virusInfectious hepatitisInterferonsPatients ePublished: 15 January 2013 Issue Published: 15 January 2013 CopyrightCopyright © 2013 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...